Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
| ▸ | EPOR | P19235 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 2/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | PTPRA | P18433 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
| ▸ | GSR | P00390 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.37 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2475253 | 1.00 | CTSK (0.39) | CTSKEPORTSHRHRH1F2 | |
| SCHEMBL28420962 | 0.81 | EPOR (0.37) | CTSKEPORF2POLBPPARG | |
| SCHEMBL4888010 | 0.81 | F2 (0.36) | CTSKEPORF2EPHX2PPARG | |
| SCHEMBL24872839 | 0.78 | IDE (0.55) | CTSKEPORHRH1PTPRAL3MBTL1 | |
| SCHEMBL4301333 | 0.78 | IDE (0.55) | CTSKEPORHRH1PTPRAL3MBTL1 | |
| SCHEMBL8153442 | 0.78 | GSK3B (0.50) | CTSKHRH1EPHX2MMP2MMP9 | |
| SCHEMBL17025155 | 0.73 | POLB (0.39) | TSHRPOLBPTPRAPPARGPPARA | |
| Lysine SCHEMBL28145765 | 0.72 | GSR (0.56) | CTSKEPHX2MMP2POLBGSR | |
| SCHEMBL9716623 | 0.71 | F2 (0.50) | EPORHRH1F2MMP2MMP9 | |
| SCHEMBL7321837 | 0.71 | F2 (0.50) | EPORHRH1F2MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080193377-A1 | Radiolabeled Nanohybrids Targeting Solid Tumor Neovasculature and Method of Using Same | UNIVERSITY OF MARYLAND, BALTIMORE | 2008-08-14 | — | — | US | claimed |
| EP-1768706-A2 | RADIOLABELED NANOHYBRIDS TARGETING SOLID TUMOR NEOVASCULATURE AND METHOD OF USING SAME | University of Maryland, Baltimore (US) | 2007-04-04 | — | — | EP | claimed |
| WO-2006012355-A2 | RADIOLABELED NANOHYBRIDS TARGETING SOLID TUMOR NEOVASCULATURE AND METHOD OF USING SAME | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2006-02-02 | — | — | WO | claimed |
| US-9433594-B2 | Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2016-09-06 | — | — | US | disclosed |
| US-20160222036-A1 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2016-08-04 | — | — | US | disclosed |
| EP-2706057-B1 | Bis(imidazolyl)compounds and radionuclide complexes | MOLECULAR INSIGHT PHARM INC (US) | 2016-04-20 | — | — | EP | disclosed |
| US-8962799-B2 | Technetium—and rhenium-bis(heteroaryl) complexes and methods of use thereof | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-20140341805-A1 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2014-11-20 | — | — | US | disclosed |
| US-8840865-B2 | Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2014-09-23 | — | — | US | disclosed |
| US-20140179902-A1 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| EP-2706057-A1 | Bis(imidazolyl)compounds and radionuclide complexes | Molecular Insight Pharmaceuticals, Inc. (US) | 2014-03-12 | — | — | EP | disclosed |
| EP-2373621-A2 | TECHNETIUM-AND RHENIUM-BIS(HETEROARYL)COMPLEXES AND METHODS OF USE THEREOF | Molecular Insight Pharmaceuticals, Inc. (US) | 2011-10-12 | — | — | EP | disclosed |
| US-20100183509-A1 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2010-07-22 | — | — | US | disclosed |
| WO-2010065899-A2 | TECHNETIUM-AND RHENIUM-BIS(HETEROARYL)COMPLEXES AND METHODS OF USE THEREOF | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
| EP-2097112-A2 | METHODS OF IMAGING EMPLOYING CHELATING AGENTS | Barnes-Jewish Hospital (US) | 2009-09-09 | — | — | EP | disclosed |
| US-20080241061-A1 | METHODS OF IMAGING EMPLOYING CHELATING AGENTS | KEREOS, INC. | 2008-10-02 | — | — | US | disclosed |
| US-20080193377-A1 | Radiolabeled Nanohybrids Targeting Solid Tumor Neovasculature and Method of Using Same | UNIVERSITY OF MARYLAND, BALTIMORE | 2008-08-14 | — | — | US | disclosed |
| WO-2008070464-A2 | METHODS OF IMAGING EMPLOYING CHELATING AGENTS | BARNES-JEWISH HOSPITAL (US) | 2008-06-12 | — | — | WO | disclosed |
| EP-1768706-A2 | RADIOLABELED NANOHYBRIDS TARGETING SOLID TUMOR NEOVASCULATURE AND METHOD OF USING SAME | University of Maryland, Baltimore (US) | 2007-04-04 | — | — | EP | disclosed |
| WO-2006012355-A2 | RADIOLABELED NANOHYBRIDS TARGETING SOLID TUMOR NEOVASCULATURE AND METHOD OF USING SAME | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080241061-A1 | METHODS OF IMAGING EMPLOYING CHELATING AGENTS | PHOSPHO1, SGMS1, SGMS2 | CTSK 1393/4885EPOR 680/4885TSHR 2438/4885 |
| US-20140341805-A1 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF | RAB35, SLC39A14, SLC39A3 | CTSK 737/4885EPOR 1747/4885TSHR 46/4885 |
| US-20140179902-A1 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF | SSTR5, SSTR3, SSTR4 | CTSK 417/4885EPOR 325/4885TSHR 12/4885 |
| US-20160222036-A1 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF | RAB35, SLC39A14, SLC39A3 | CTSK 737/4885EPOR 1747/4885TSHR 46/4885 |
| US-20100183509-A1 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF | SSTR5, SSTR3, SSTR4 | CTSK 417/4885EPOR 325/4885TSHR 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.